BT-200(Biora Therapeutics) | Interleukin Related interleukin-related.com

Product Name :
BT-200(Biora Therapeutics)

Search keywords :
BT200

drugId :
null

Target Vo:
Glucagon-like peptide 1 receptor

Target Vo Short Name :
GLP1R

Moa_Name:
Glucagon-like peptide 1 receptor agonists

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Biora Therapeutics Inc

Active Company_Name :
Biora Therapeutics Inc

Active Indication_Name:
Diabetes Mellitus, Type 2

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Preclinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
IKK gamma Antibody
Phospho-MEK1 (Thr292) Antibody
GFAP Antibody (YA756): GFAP Antibody (YA756) is a non-conjugated and Mouse origined monoclonal antibody about 50 kDa, targeting to GFAP (9A2). It can be used for WB,IHC-F,IHC-P,ICC/IF assays with tag free, in the background of Human, Mouse.

Author: Interleukin Related

Related Posts